The food industry faces a fundamental shift in how obesity is understood – and who is held responsible for it. A convergence of new drug science, addiction research, and systems-level policy analysis suggests that the long-held assumption that obesity is a matter of personal failing is beginning to crack. For food scientists and manufacturers, the implications are direct and urgent: the deliberate engineering of ultra-processed foods is now facing its most serious scientific and regulatory challenge to date.

A wake-up call for the food industry

For decades, the obesity debate has been framed around individual behaviour – poor dietary choices, lack of exercise, insufficient willpower. That framing has served the food industry well, deflecting regulatory scrutiny and maintaining the status quo. But a body of research now converging from multiple scientific disciplines suggests that framing is shifting – and that the rise of GLP-1 receptor agonist drugs for weight loss, such as Ozempic and Wegovy (semaglutide) may be the catalyst
that finally tips the balance.

A conceptual essay presented at the European Congress on Obesity in Istanbul (12-15 May 2026), authored by Assistant Professor Luc Louis Hagenaars (Amsterdam UMC) and Professor Laura Anne Schmidt (University of California, San Francisco), argues that GLP-1 drugs are driving three convergent changes with direct consequences for the food industry: decreased consumer demand for ultra-processed foods (UPFs), a scientific paradigm shift aligning obesity more closely with addiction models, and a transformation in public discourse away from individual culpability towards recognition of the role of commercially engineered food products.

The authors are explicit about the stakes: “These medications could redirect blame for obesity from individual failings to the pervasive influence of commercial food systems, drawing parallels with historical public health successes against tobacco and alcohol. This reframing is crucial for addressing escalating obesity rates and associated chronic diseases.”

This is not a distant or theoretical threat. Early market signals are already visible. Food manufacturers are developing – and major retailers are selling – “GLP-1 friendly” product lines in smaller packages with added protein and fibre. These reformulations signal that the industry is already responding to shifting consumer behaviour driven by GLP-1 drug uptake. But they may also be drawing attention to the very engineering strategies that critics now argue warrant tobacco-style regulation – strategies that a landmark paper in The Milbank Quarterly has now documented in forensic detail.

Why the shift has taken so long – and why it is happening now

To understand why this moment matters, it is necessary to understand why the individual-blame framing has proved so resilient. Hagenaars and Schmidt’s earlier systems analysis, published in Obesity Reviews in 2024, provides the analytical foundation. Using complexity science and Punctuated Equilibrium Theory, the authors mapped the feedback loops that have historically locked obesity policymaking into an individual-blame paradigm.

Their central finding is stark: the current policymaking system contains eight self-reinforcing feedback loops and zero balancing feedback loops – a configuration that continuously and spontaneously strengthens the framing of obesity as an individual problem. Crucially, improvements in individual-level therapies – diets, surgery, and now obesity medications – do not weaken this dynamic. They reinforce it. Each advance in pharmacological treatment increases policymakers’ reluctance to consider more structurally ambitious interventions targeting the food environment itself.

This is the paradox at the heart of the GLP-1 moment. The very drugs that are reducing cravings for UPFs and prompting consumers to question why certain foods are so difficult to resist could, if the narrative is not actively managed, simply strengthen the case for medicalising obesity further – leaving the food system untouched. The 2024 analysis identifies that breaking this cycle requires a “focusing event”: a shock that temporarily redirects political attention towards obesity as a societal rather than individual problem. The GLP-1 era may constitute precisely such an event – but only if researchers, advocates, and policymakers exploit the window it opens.

The tobacco parallel: dose, delivery, and sensory engineering

The scientific case for treating UPFs as structurally analogous to tobacco products – rather than simply as foods with poor nutritional profiles – receives its most detailed treatment in a peer-reviewed article published in The Milbank Quarterly (Vol. 104, No. 1, 2026), authored by Gearhardt, Brownell, and Brandt. The paper draws on addiction science, nutrition research, and public health history to conduct a systematic comparison of cigarettes and UPFs across five domains: dose optimisation, delivery speed, hedonic engineering, environmental ubiquity, and deceptive reformulation.

The corporate connections between the two industries are more than metaphorical. Tobacco companies R.J. Reynolds and Philip Morris acquired companies including Kraft, General Foods, and Nabisco, and were leading manufacturers and marketers of UPFs from the 1980s through the mid-2000s. The paper documents how strategies developed for tobacco engineering were directly transferred to food manufacturing – a finding with significant implications for how liability might be framed in future litigation.

On dose optimisation, the paper documents how refined carbohydrates and fats in UPFs are calibrated with precision to hit a sensory “sweet spot” that maximises reward while minimising aversion – directly analogous to the 1.0-2.0% nicotine concentration maintained in cigarettes. When refined carbohydrates and fats are consumed together, their effects on the brain’s reward circuitry are supra-additive: the mesolimbic dopamine response reaches 300% above baseline – a threefold surge in the brain’s reward and craving response – compared with 120-150% for fat alone. This carbohydrate-fat combination is described as almost entirely absent in nature, occurring only in industrially engineered products.

Delivery speed receives equally detailed treatment. UPFs are described as effectively “prechewed, presalivated, and predigested” through industrial processing that strips fibre, protein, and water, and incorporates enzymatic additives such as amylases and proteases to accelerate absorption. This mirrors the tobacco industry’s use of ammonia freebasing and particle-size manipulation to intensify and accelerate nicotine delivery.

Short hang time: engineering repeat consumption

One of the more technically specific – and commercially significant – findings concerns what the authors call “short hang time”: the deliberate engineering of flavour bursts that fade rapidly to encourage continued consumption. Industry professionals have openly acknowledged this strategy. In a 60 Minutes segment, flavourists from a major flavour house confirmed that products are engineered for a rapid sensory peak followed by swift dissipation, specifically to drive repeated intake. The paper quotes one flavourist confirming directly that the goal is to create an “addictive taste.”

The physiological mechanism compounds the sensory one. The rapid spike in blood glucose produced by high refined-carbohydrate UPFs is followed within one to two hours by a compensatory drop – mild hypoglycaemia – resulting in fatigue, irritability, and renewed craving. This cycle mirrors nicotine withdrawal and is, the authors argue, not an incidental product characteristic but a deliberately engineered feature of product design.

Health washing: a strategy with an expiry date

The paper’s treatment of health washing will be of particular concern to food scientists involved in product development and claims strategy. The authors draw a precise parallel between “light” and “low-tar” cigarettes – which prompted compensatory behaviours without reducing harm – and UPF reformulations carrying “low fat,” “sugar free,” or “protein-enriched” claims. Clinical trials cited in the paper suggest that protein-enriched UPFs continue to promote overeating and carry similar health risks to conventional equivalents. The tobacco industry’s health-washing strategy ultimately collapsed under the weight of litigation and internal document disclosure. The paper argues explicitly that the food industry is following the same trajectory.

Non-sugar sweeteners receive similar scrutiny. Some animal studies suggest they are preferred over cocaine, and recent human neuroimaging research indicates they may interfere with appetite regulation in individuals with obesity. The authors argue their primary function is to preserve consumption patterns and forestall regulatory action rather than to improve public health outcomes.

The additive transparency issue adds further regulatory exposure. Additive formulations protected as proprietary trade secrets, GRAS self-assessments conducted by manufacturers with potential conflicts of interest, and vague label descriptors such as “natural flavours” are all identified as systemic vulnerabilities that mirror the information-suppression strategies employed by the tobacco industry prior to the Master Settlement Agreement.

The regulatory roadmap is already drawn

The policy implications proposed by Gearhardt and colleagues are explicit: litigation, marketing restrictions – particularly targeting children – taxation of nutrient-poor UPFs, reduced availability in schools and hospitals, and clearer labelling of ultraprocessing. The authors are unequivocal that voluntary industry reform will not be sufficient.

The Hagenaars et al. Obesity Reviews analysis adds a further dimension that the food industry would do well to note. Effective regulation of obesogenic food environments does not require health ministries to act alone. Ultraprocessed food taxes can be framed as fiscal instruments: in Mexico, revenue generation secured buy-in from the Ministry of Finance. Environmental agencies may act through the plastic waste associated with UPF packaging. Education departments have their own institutional reasons to restrict UPFs in schools. The next wave of regulation may arrive simultaneously from multiple government sectors – making it considerably harder to resist than a single public health initiative.

As Hagenaars and Schmidt conclude: “The ‘Ozempic Era’ offers a pivotal moment to challenge deeply ingrained cultural assumptions about obesity as a personal failing. By leveraging the broader impacts of new obesity drugs, society can foster collective responsibility and generate the necessary policy momentum to mitigate the root cause of the obesity crisis through comprehensive food system reforms.”

For food scientists and manufacturers, the direction of travel is clear. The scientific infrastructure – epidemiological evidence, addiction-science frameworks, systems-level policy analysis, and the lived experience of millions of GLP-1 drug users questioning why certain foods drove their cravings – is now in place. The focusing event has arrived. The question is not whether regulatory pressure will intensify, but how rapidly, and whether the industry will be positioned ahead of it or behind it.

Journal references:

• Gearhardt, A. N., Brownell, K. D., & Brandt, A. M. (2026). From tobacco to ultraprocessed food: How industry engineering fuels the epidemic of preventable disease. The Milbank Quarterly, 104(1), 76–115. https://doi.org/10.1111/1468-0009.70066

• Hagenaars, L. L., Schmidt, L. A., Groeniger, J. O., et al. (2024). Why we struggle to make progress in obesity prevention and how we might overcome policy inertia: Lessons from the complexity and political sciences. Obesity Reviews, 25(5), e13705. https://doi.org/10.1111/obr.13705